Granted Patent B2

US 12,746,251 · App. 18/132,300 · Granted Sep 29, 2026

Inventors: Jean-Pierre Sommadossi (Boston, MA); Kai Lin (Belmont, MA); Adel Moussa (Burlington, MA); Bruno Canard (Marseilles, FR); Ashleigh Shannon (Marseilles, FR)

Assignee: Atea Pharmaceuticals, Inc.

A61K31/7076A61P31/14

Abstract

Claims (40)

1 . A method for the treatment of an infection with a remdesivir-resistant strain of SARS-COV-2 virus in a human in need thereof, comprising administering an effective amount of a compound of Formula I:

or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, wherein:

R 1 is hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, aryl or aryl-C 1-4 alkyl;

R 2 is hydrogen or C 1-6 alkyl;

R 3a and R 3b are independently selected from hydrogen, C 1-6 alkyl, and C 3-7 cycloalkyl; and

R 4 is hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, C 3-7 cycloalkyl, or aryl-C 1-4 alkyl.

2 . The method of claim 1 , wherein R 1 is aryl.

3 . The method of claim 1 , R 2 is hydrogen.

4 . The method of claim 1 , wherein R 3a is C 1-6 alkyl and R 3b is hydrogen.

5 . The method of claim 1 , wherein R 3a is methyl and R 3b is hydrogen.

6 . The method of claim 1 , wherein R 4 is C 1-6 alkyl.

7 . The method of claim 1 , wherein R 4 is methyl, ethyl or isopropyl.

8 . The method of claim 7 , wherein R 4 is isopropyl.

9 . The method of claim 1 , wherein the pharmaceutically acceptable carrier is in a dosage form suitable for oral administration.

10 . The method of claim 9 , wherein the dosage form is a solid dosage form.

11 . The method of claim 10 , wherein the solid dosage form is a tablet.

12 . The method of claim 10 , wherein the solid dosage form is a capsule.

13 . The method of claim 9 , wherein the dosage form is a liquid dosage form.

14 . The method of claim 13 , wherein the liquid dosage form is a solution or a suspension.

15 . A method for the treatment of an infection with a remdesivir-resistant strain of SARS-COV-2 virus in a human in need thereof, comprising administering an effective amount of Compound 1:

or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

16 . The method of claim 15 , comprising administering an effective amount of Compound 1A

or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

17 . The method of claim 15 , comprising administering an effective amount of Compound 1B

or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.

18 . The method of claim 16 , comprising administering an effective amount of Compound 1A

in an oral dosage of about 550 mg of Compound 1A twice a day to a human in need thereof.

19 . The method of claim 18 , wherein the oral dosage form is a tablet, gelcap, pill, or capsule.

20 . The method of claim 15 , comprising administering an effective amount of Compound 2

optionally in a pharmaceutically acceptable carrier.

21 . The method of claim 20 , comprising administering an effective amount of Compound 2A

optionally in a pharmaceutically acceptable carrier.

22 . The method of claim 20 , comprising administering an effective amount of Compound 2B

optionally in a pharmaceutically acceptable carrier.

23 . The method of claim 21 , wherein the pharmaceutically acceptable carrier is in a dosage form suitable for oral administration.

24 . The method of claim 23 , wherein the dosage form is a solid dosage form.

25 . The method of claim 24 , wherein the solid dosage form is a tablet.

26 . The method of claim 24 , wherein the solid dosage form is a capsule.

27 . The method of claim 23 , wherein the dosage form is a liquid dosage form.

28 . The method of claim 27 , wherein the liquid dosage form is a solution or a suspension.

Assignments (3)

Continuity (6)

References Cited (400)